Cargando…

Galectins and Ovarian Cancer

Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Chisa, Xu, Rui, Al-Alem, Linah, Stasenko, Marina, Spriggs, David R., Rueda, Bo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352943/
https://www.ncbi.nlm.nih.gov/pubmed/32486344
http://dx.doi.org/10.3390/cancers12061421
_version_ 1783557758905221120
author Shimada, Chisa
Xu, Rui
Al-Alem, Linah
Stasenko, Marina
Spriggs, David R.
Rueda, Bo R.
author_facet Shimada, Chisa
Xu, Rui
Al-Alem, Linah
Stasenko, Marina
Spriggs, David R.
Rueda, Bo R.
author_sort Shimada, Chisa
collection PubMed
description Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions.
format Online
Article
Text
id pubmed-7352943
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73529432020-07-15 Galectins and Ovarian Cancer Shimada, Chisa Xu, Rui Al-Alem, Linah Stasenko, Marina Spriggs, David R. Rueda, Bo R. Cancers (Basel) Review Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions. MDPI 2020-05-31 /pmc/articles/PMC7352943/ /pubmed/32486344 http://dx.doi.org/10.3390/cancers12061421 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shimada, Chisa
Xu, Rui
Al-Alem, Linah
Stasenko, Marina
Spriggs, David R.
Rueda, Bo R.
Galectins and Ovarian Cancer
title Galectins and Ovarian Cancer
title_full Galectins and Ovarian Cancer
title_fullStr Galectins and Ovarian Cancer
title_full_unstemmed Galectins and Ovarian Cancer
title_short Galectins and Ovarian Cancer
title_sort galectins and ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352943/
https://www.ncbi.nlm.nih.gov/pubmed/32486344
http://dx.doi.org/10.3390/cancers12061421
work_keys_str_mv AT shimadachisa galectinsandovariancancer
AT xurui galectinsandovariancancer
AT alalemlinah galectinsandovariancancer
AT stasenkomarina galectinsandovariancancer
AT spriggsdavidr galectinsandovariancancer
AT ruedabor galectinsandovariancancer